Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.
- Mumbai Office Leasing and Residential Sales Grow in 2024
- Nvidia Launches New RTX 50 Series GPU
- Consint.AI Secures Rs 5 Crore Funding in Seed Round
- Arkade Developers Adds 3 New Redevelopment Projects
- India Launches a New Steel PLI Scheme
The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.
